Developer docs
API playgroundTry for free, no card

Search company profiles

Gradian Diagnostics

Full company profile

uuid0000t44

Namestring
Gradian Diagnostics
Websiteurl
gradian-dx.com
Company typeenum
Private
Founded yearint
2018
Short descriptiontext

Gradian Diagnostics is a privately held, Miami Beach-based biotechnology company founded in 2018 that claims to develop next-generation medical and diagnostics technologies. Its public footprint is limited to a single 2019 funding round of ~$3.1M, and its corporate website is currently offline.

Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMiami Beach, United States
HQ citystring
Miami Beach
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
medical diagnostics, biotechnology products, clinical diagnostics, next-generation diagnostics, in-vitro diagnostics
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Diagnostics
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Gradian Diagnostics is a biotechnology company that develops next-generation medical and diagnostics technologies. The company focuses on creating advanced diagnostic products and platforms intended for use by healthcare providers and clinical laboratories. Specific product lines, assay menus, or instrument details are not disclosed in available source material.

Differentiator
Functional benefit
Problem solved
No data
Peers10 records
TypeBroad incumbent
Description

Diversified diagnostics and women's health company with major molecular diagnostics products (e.g., Panther); broadly incumbent in the same diagnostics category Gradian targets.

TypeEmerging player
Description

Smaller public diagnostics company focused on rapid antimicrobial resistance identification; comparable as an emerging next-gen diagnostics peer with similar capital-intensity profile.

TypeDirect peer
Description

Developer of the GeneXpert molecular diagnostics platform widely used for rapid infectious-disease testing; directly comparable as a next-generation diagnostics technology provider serving clinical and hospital customers.

TypeBroad incumbent
Description

Global provider of molecular diagnostics sample technologies and assays, with a broad diagnostics portfolio relevant to any next-gen diagnostics developer.

TypeEmerging player
Description

Diagnostics company developing direct-from-sample molecular detection products; comparable as a small-cap next-gen diagnostics peer navigating similar commercialization challenges.

TypeDirect peer
Description

Diagnostics company focused on immunoassays and rapid testing across clinical settings; comparable as a peer in next-generation medical diagnostics commercialization.

TypeDirect peer
Description

Molecular diagnostics company (acquired by Roche) whose ePlex platform automated syndromic testing; a directly comparable next-gen diagnostics business that was a strategic acquisition target.

TypeRegional player
Description

Diagnostics and measurement-focused life sciences tools company; comparable as a smaller peer in the medical/clinical diagnostics and measurement space.

TypeDirect peer
Description

Syndromic molecular diagnostics developer (FilmArray) with a similar next-gen testing platform business model targeting hospitals and reference labs.

10Abbott Diagnostics
TypeBroad incumbent
Description

One of the largest diagnostics incumbents globally, with molecular, immunoassay, and point-of-care platforms; a broad comparable for a smaller next-gen diagnostics challenger.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gradian Diagnostics

Medical Diagnosticsgradian-dx.com

Gradian Diagnostics is a privately held, Miami Beach-based biotechnology company founded in 2018 that claims to develop next-generation medical and diagnostics technologies. Its public footprint is limited to a single 2019 funding round of ~$3.1M, and its corporate website is currently offline.

Gradian Diagnostics firmographics

Firmographics
Name
Gradian Diagnostics
Website
https://gradian-dx.com
Company type
Private
Founded year
2018
Headcount range
51–100 employees
Short description
Gradian Diagnostics is a privately held, Miami Beach-based biotechnology company founded in 2018 that claims to develop next-generation medical and diagnostics technologies. Its public footprint is limited to a single 2019 funding round of ~$3.1M, and its corporate website is currently offline.
Ownership category
akta.pro rank

Where Gradian Diagnostics is headquartered

Location

Headquarters

HQ city
Miami Beach
HQ country
United States
HQ region
North America

Markets served

Gradian Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Gradian Diagnostics product offering

Product offering

Core offering

Gradian Diagnostics is a biotechnology company that develops next-generation medical and diagnostics technologies. The company focuses on creating advanced diagnostic products and platforms intended for use by healthcare providers and clinical laboratories. Specific product lines, assay menus, or instrument details are not disclosed in available source material.

Differentiator

Problem solved

Functional benefit

Companies that use Gradian Diagnostics

Customer profile

Ideal customer profiles1 record

Gradian Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Gradian Diagnostics competitors and assessment

Company assessment

Broad incumbents

  • Hologic: Diversified diagnostics and women's health company with major molecular diagnostics products (e.g., Panther); broadly incumbent in the same diagnostics category Gradian targets.
  • QIAGEN: Global provider of molecular diagnostics sample technologies and assays, with a broad diagnostics portfolio relevant to any next-gen diagnostics developer.
  • Abbott Diagnostics: One of the largest diagnostics incumbents globally, with molecular, immunoassay, and point-of-care platforms; a broad comparable for a smaller next-gen diagnostics challenger.

Emerging players

  • Accelerate Diagnostics: Smaller public diagnostics company focused on rapid antimicrobial resistance identification; comparable as an emerging next-gen diagnostics peer with similar capital-intensity profile.
  • T2 Biosystems: Diagnostics company developing direct-from-sample molecular detection products; comparable as a small-cap next-gen diagnostics peer navigating similar commercialization challenges.

Direct peers

  • Cepheid (Danaher): Developer of the GeneXpert molecular diagnostics platform widely used for rapid infectious-disease testing; directly comparable as a next-generation diagnostics technology provider serving clinical and hospital customers.
  • QuidelOrtho: Diagnostics company focused on immunoassays and rapid testing across clinical settings; comparable as a peer in next-generation medical diagnostics commercialization.
  • GenMark Diagnostics: Molecular diagnostics company (acquired by Roche) whose ePlex platform automated syndromic testing; a directly comparable next-gen diagnostics business that was a strategic acquisition target.
  • BioFire Diagnostics (bioMérieux): Syndromic molecular diagnostics developer (FilmArray) with a similar next-gen testing platform business model targeting hospitals and reference labs.

Regional players

  • Mesa Labs: Diagnostics and measurement-focused life sciences tools company; comparable as a smaller peer in the medical/clinical diagnostics and measurement space.

Market position

Customer concentration

Gradian Diagnostics social profiles

Digital presence

Gradian Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gradian Diagnostics leadership team

Management profile

Number of profiles

Profiles1 record

Gradian Diagnostics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gradian Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gradian Diagnostics

What does Gradian Diagnostics do?

Gradian Diagnostics is a biotechnology company that develops next-generation medical and diagnostics technologies. The company focuses on creating advanced diagnostic products and platforms intended for use by healthcare providers and clinical laboratories. Specific product lines, assay menus, or instrument details are not disclosed in available source material.

When was Gradian Diagnostics founded?

Gradian Diagnostics was founded in 2018. It employs 51 to 100 people.

Where is Gradian Diagnostics based?

Gradian Diagnostics is headquartered in Miami Beach, United States, in the North America region.

Who are Gradian Diagnostics's main competitors?

Broad incumbents on record are Hologic, QIAGEN and Abbott Diagnostics. Emerging players are Accelerate Diagnostics and T2 Biosystems. Direct peers are Cepheid (Danaher), QuidelOrtho, GenMark Diagnostics and BioFire Diagnostics (bioMérieux). Mesa Labs is listed as a regional player.

Does Gradian Diagnostics have an API?

No public API is recorded for Gradian Diagnostics.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales